Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

June 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

June 2024 Dispatch for the CV Team

June 01, 2024

Mechanism’s Mojo ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

News Daily News

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

May 30, 2023

Most Patient-Reported Outcome Measures in CVD Fall Short

News Daily News

Most Patient-Reported Outcome Measures in CVD Fall Short

September 23, 2022

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

FDA Advisors Give Blessing to Implantable Pulse Generator in Certain Heart Failure Patients

News Daily News

FDA Advisors Give Blessing to Implantable Pulse Generator in Certain Heart Failure Patients

Yael L. Maxwell

December 05, 2018

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

News Daily News

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Michael O'Riordan

July 10, 2017

News Daily News

Betrixaban Approved for Prevention of VTE

Michael O'Riordan

June 23, 2017

Rapid Rule-Out Strategy with High-Sensitivity Troponin Shows Promise Ahead of US Commercial Availability of Test

News Daily News

Rapid Rule-Out Strategy With High-Sensitivity Troponin Shows Promise Ahead of US Commercial Availability of Test

April 17, 2017

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.